G WEXLER'S COVID PATENTS RESEARCH

Grant Money plus Geoff's Interviews

Aug 15, 2023

NOTE: Geoff’s videos and podcasts are listed below.

FOLLOW THE GRANT MONEY

Geoff Wexler says “The 2 most telling legal practice groups to forensically follow the money are fund finance with grants and intellectual property patents.”

Here are links to conspiracy suspects’ grants.

Barney Graham https://reporter.nih.gov/search/c9xa1thLD0qmKeHIYW2Tyw/projects?shared=true

Ralph Baric https://reporter.nih.gov/search/TddEgWh0aEuwKQGO5s-VhQ/projects

Anthony Fauci https://reporter.nih.gov/search/jdCkNsMQ00GyAACinFmC6Q/projects

Peter Daszak https://reporter.nih.gov/search/LWlPhekdT0CIOXXgoZuf0A/projects

TOP 3 GRANTS

Graham & Baric received numerous huge grants. Here are the biggest ones.

(1) Rapid Development of a Vaccine for Zika Virus — GRAHAM, BARNEY Principal Investigator(s)/ Project Leader(s) — NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

2016 NIAID $39,678,048

Abstract Text. While the outbreak of ZIKV in the Americas is likely to subside in the next 1-2 years, there is going to be an ongoing risk of congenital Zika syndrome in babies born to mothers exposed to ZIKV during pregnancy. There is no licensed vaccine or treatment to combat ZIKV infection. Because of the urgent need for a ZIKV vaccine, and a finite time in which efficacy could be demonstrated in the current outbreak, we focused on developing a DNA vaccine, which can be rapidly produced and can easily modified using reverse genetics techniques. The first generation DNA vaccines are based on prior success in West Nile Virus. We designed and evaluated two lead DNA vaccine candidates which produce subviral particles (SVP) after transfection. The first candidate (VRC5283) expresses the prM and E proteins from the ZIKV French Polynesia 2014 strain. The other (VRC5288) is a ZIKV/JEV chimera virus and was designed with the final 98 amino acids of (comprising the transmembrane and stem domains from JEV) swapped for the corresponding regions from ZIKV which has been demonstrated to improve SVP secretion for other flaviviruses. Immunization with these constructs generated robust neutralizing antibody responses in mice and rhesus macaques. Two doses of DNA vaccine candidates expressing the prM and E proteins of Zika virus protected 17 out of 18 rhesus macaques from viremia after Zika virus challenge. This protection was correlated with serum neutralizing activity. A single dose of DNA vaccine did not completely prevent infection, but significantly reduced the level of viremia in Zika virus challenged rhesus macaques.

(2) RAPIDLY EMERGING ANTIVIRAL DRUG DEVELOPMENT INITIATIVE- AViDD CENTER — BARIC, RALPH S Principal Investigator(s)/ Project Leader(s) — WILLSON, TIMOTHY Principal Investigator(s)/ Project Leader(s) — UNIV OF NORTH CAROLINA CHAPEL HILL

2022 NIAID $65,483,194

PROGRAM SUMMARY/ABSTRACT. Emerging viruses arise suddenly and cause considerable morbidity and mortality worldwide. To prepare for current and future threats, public-private partnerships are needed to change the current reactive response platform into one that is proactive. In response to RFA-AI-21-050, the Rapidly Emerging Antiviral Drug Development Initiatives AViDD Center (READDI-AC) is an integrated public-private partnership with a renowned, interdisciplinary research team of experts, who apply cutting edge innovative technologies in virology, biochemistry, structural biology, medicinal chemistry, computational biology, structure-guided drug design and genomics to develop oral, potent, broad-spectrum family-specific antivirals for coronaviruses, flaviviruses, alphaviruses and filoviruses. To achieve these goals, the READDI-AC program includes academic leaders in basic and applied antiviral research and chemistry as well as industry leaders Janssen Pharmaceuticals N.V.(JPNV), Takeda, Chimerix Inc. and Pardes Biosciences. Our commercial partners provide an enviable track records in drug discovery and product development, and leadership in medicinal chemistry, pharmacology, drug formulation, toxicity studies and pharmacokinetics, especially critical for driving optimized leads through preIND enabling studies toward the clinic. Importantly, our industry partners also provide in kind matching contributions, access to high quality commercial chemical libraries, early hits, optimized leads, and state of the art high- throughput screens. The immediate and long-term goals of READDI-AC are to: a) validate druggable targets in conserved viral proteins, b) identify hits and leads using SAR and state of the art biochemical and enzymatic assays, c) optimize/formulate chemical probes and lead compounds as broadly acting oral compounds with activity against multiple relevant members of each emerging virus family; d) provide critical late-stage preclinical development and IND-enabling in vivo studies for two broadly active, oral drug candidates; e) promote open science sharing of unused chemical assets, chemical probes, methods, reagents and assays for innovations by crowdsourcing; f) build capacity and training in 21st century viral drug discovery and development by coupling innovative approaches in target discovery and validation with state of the art techniques, integrated workflows and novel discovery platforms for hit to lead progression and SAR optimization. READDI-AC has five Research Projects and four highly interactive cores that establish a cooperative landscape that builds leadership, expertise, response capacity and partnerships that invigorate 21st century drug development.

(3) Core A: Administrative Core — BARIC, RALPH S Principal Investigator(s)/ Project Leader(s) — UNIV OF NORTH CAROLINA CHAPEL HILL

2022 NIAID $9,202,226

ABSTRACT. Emerging viruses (EV) constantly arise from zoonotic reservoirs to threaten global health and economic stability, illustrated by the ongoing COVID19 pandemic that has infected over 220 million people and caused over 4.8 million deaths worldwide. The Administrative and Management Core (Adman Core A) is specifically responsive to this RFA and is structured to manage and coordinate all activities conducted by the five projects (PR1-5) and three scientific cores (Cores B-D) housed within the Rapidly Emerging Antiviral Drug Development Initiatives AViDD Center (READDI-AC). Core A has five specific aims that provide: (Aim 1) decisive leadership, administrative and financial oversight; (Aim 2) communication links between projects and cores, corporate partners, the NIH, and external collaborators/advisors; (Aim 3) data management and security across the Center; (Aim 4) the management structure needed to review research progress, identify problems, periodically review targets, and prioritize hits and leads for further development; and (Aim 5) pilot and mentored award management. In addition, Adman Core A will accelerate drug development and build capacity through the open sharing of reagents, tools, assays, and models that catalyze robust in vitro and in vivo assays for emerging viruses. Adman Core A manages a diverse team of academic and industry partners with deep expertise in antiviral drug discovery from multiple fields, including virologists, biochemists, structural biologists, enzymologists, pharmacologists, modelers, and medicinal chemists. Importantly, Adman Core A also engages pharmaceutical leaders, specifically Takeda, J&J, Chimerix, and Pardes Biosciences, who contribute in-kind resources, assays, chemical assets, chemistry, expertise, and leadership. The program takes an innovative approach to drug development that includes an early open science platform as promoted by the Structural Genomics Consortium, but then transitions to encourage intellectual property protection of chemical assets being formulated for preIND and IND enabling studies. By leveraging the combined assets and resources of our corporate and academic partners, Adman Core A’s overall goal is to advance at least 2 DAA drugs to the milestone of a pre-IND meeting with the FDA.